Evidence map›Paper›PMID 39406397›Full record

ReviewEuropean heart journal. Cardiovascular pharmacotherapy2025

Role of PCSK9 inhibitors in venous thromboembolism: current evidence and unmet clinical needs.

Marco Zuin, Alberto Corsini, Chiara Dalla Valle, Catia De Rosa, Alessandro Maloberti, Marco Mojoli, Massimiliano Rizzo, Francesco Ciccirillo, Alfredo Madrid, Carmine Riccio and 5 more

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in European heart journal. Cardiovascular pharmacotherapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Review
  3. Extensive LDL-cholesterol lowering by PCSK9 inhibitor on the risk of venous thrombosis.European heart journal. Cardiovascular pharmacotherapy · 2025
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

15 authors.

Marco ZuinDepartment of Translational Medicine, University of Ferrara, Via Luigi Borsari 46, Ferrara 44121, Italy.ORCID 0000-0002-4559-1292
Alberto CorsiniDepartment of Pharmacological and Biomolecular Sciences, University of Milan, Milan 20133, Italy.ORCID 0000-0002-9912-9482
Chiara Dalla ValleDepartment of Cardiology, West Vicenza General Hospital, Arzignano 36071, Italy.
Catia De RosaDepartment of Cardiology, Ospedale Mauriziano Umberto I, Torino 10128, Italy.
Alessandro MalobertiCardiac Rehabilitation Unit, Cardiology 4, ASST Grande Ospedale Metropolitano Niguarda, Milano 20162, Italy.
Marco MojoliDivision of Cardiology, Ospedale Santa Maria degli Angeli, Azienda Ospedaliera Friuli Occidentale (ASFO), Pordenone 33170, Italy.
Massimiliano RizzoDepartment of Cardiology, Policlinico Umberto I, Roma 00161, Italy.
Francesco CiccirilloDepartment of Cardiology, Ospedale Vito Fazzi, Lecce 73100, Italy.
Alfredo MadridDepartment of Cardiology, AORN Cardarelli, Napoli 80131, Italy.
Carmine RiccioCardiovascular Department, Sant'Anna e San Sebastiano Hospital, Caserta 81100, Italy.
Massimo GrimaldiDepartment of Cardiology, Ospedale Generale Regionale "F. Miulli", Acquaviva delle Fonti 70021, Italy.ORCID 0000-0002-9347-8884
Furio ColivicchiClinical and Rehabilitation Cardiology Unit, San Filippo Neri Hospital, Roma 00135, Italy.ORCID 0000-0001-7187-2234
Fabrizio OlivaCardiology Unit, ASST Grande Ospedale Metropolitano Niguarda, Milano 36071, Italy.
Pier Luigi TemporelliDivision of Cardiac Rehabilitation, Istituti Clinici Scientifici Maugeri, IRCCS, Gattico-Veruno 28013, Italy.
Associazione Nazionale Medici Cardiologi Ospedalieri (ANMCO) Working Group on Cardiological Chronicity

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9i) have recently emerged as promising therapeutic agents for lowering low-density lipoprotein cholesterol and reducing the risk of cardiovascular events. Moreover, preliminary evidence from randomized controlled trials (RCTs) suggests that PCSK9i may also offer beneficial effects for patients following venous thromboembolism (VTE), with the most significant reductions in risk appearing over time, particularly beyond the first year of treatment. However, there is a lack of randomized controlled data supporting their efficacy and safety in conjunction with standard anticoagulation therapy. This article aims to critically evaluate the existing evidence for the use of PCSK9i as a complementary therapy for VTE risk reduction, while also identifying unmet clinical and research needs and proposing potential strategies to address these knowledge gaps.

Indexed as

Anticholesteremic AgentsDyslipidemiasPCSK9 InhibitorsSerine Proteinase InhibitorsVenous ThromboembolismAnticoagulantsBiomarkersHumansProprotein Convertase 9Risk FactorsTreatment OutcomeAnticholesteremic AgentsAnticoagulantsBiomarkersPCSK9 InhibitorsPCSK9 protein, humanProprotein Convertase 9Serine Proteinase InhibitorsPCSK9 inhibitorsPreventionVenous Thromboembolism thromboembolism

Identifiers

PMID39406397
PMCPMC11724145

What Socratic holds

Texttitle and abstract
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.